Investor Highlights

Cortex Pharmaceuticals, Inc. is a neuroscience company focused on the discovery and clinical development of AMPAKINE® molecules, a platform that represents a new approach to treating psychiatric and neurological disorders. AMPAKINE compounds are small drug-like molecules that positively modulate the AMPA–type glutamate receptor complex, amplifying the effect of glutamate at the synapse, leading to excitation of brain circuits.

AMPAKINE compounds fall into two categories: “low” and “high” impact compounds, defined by the site to which they bind on the AMPA receptor complex. Cortex’s lead low impact AMPAKINE, CX717, has demonstrated “Proof-of-Concept” in adult ADHD patients in a small pilot Phase IIa study.  CX717 is currently being tested in two pilot Phase II studies. The first study is being performed in mild to moderate Alzheimer’s disease patients and will investigate changes in brain metabolism by PET imaging.  The objective is to confirm acute PET Scan findings observed in an earlier study performed in non-human primates with memory and cognition impairment that were reversed by acute CX717 dosing. The second research program is evaluating the acute use of CX717 and in volunteers whose breathing has been depressed with the opiate, alfentanil.

Several follow-on molecules to CX717 have completed or are undergoing toxicology testing. The Company anticipates having up to three AMPAKINE compounds in clinical studies by late 2008.
 
Cortex’s business plan focuses on out-licensing internally developed AMPAKINE compounds for the very large CNS diseases such as ADHD, Alzheimer’s and Parkinson’s disease, while retaining the smaller indications and orphan diseases for internal development. The Company has already out-licensed two AMPAKINE compounds (Org24448 and Org26576) for the indications of schizophrenia and depression to Organon, which was acquired by Schering Plough in November 2007. Cortex remains eligible for milestone payments based upon further clinical development of those compounds, as well as for royalties on any ultimate sales.

Cortex’s patent portfolio includes submissions for over 250 Composition of Matter and Broad Use patents, with approximately 160 patents issued to date

Upcoming Milestones

Financial Highlights

The purpose of the Investment Center is to inform current shareholders or new investors of the growing market opportunities, market developments, and the financial status of our company. The information provided here is intended to help you make an informed decision about your potential investment in Cortex.

• Download Cortex Form 10-K fiscal year ended December 31, 2007 – 346kb – (03/18)
  
  If you would prefer to receive a copy by mail, please call us at (800) 949-3019 (x100).
  You may also send an email request or fax us at (949) 727-3657.
  
  
• Proxy Statement – 144kb PDF – (4/10/08)
  
  
• Audit Committee Charter
  
  
• Compensation Committee Charter
  
  
• Governance and Nominations Committee Charter
  
  
• Research and Development Committee Charter
  
  
• Stock Incentive Plan – 64kb PDF – (5/10/06)
  
  
• SEC Filings

Safe Harbor Statement
This investor package includes information that may contain forward-looking statements concerning the Company’s patent portfolio, research and development activities and business activities. Actual results may differ materially, depending on a number of risk factors, including the risks that that competitors may challenge or design around the Company’s patents or develop competing technologies; that the Company may be unable to secure additional capital needed to continue its operations; that the Company may be unable to arrive at corporate partnerships with larger pharmaceutical companies on acceptable terms and therefore be required to independently fund clinical development of AMPAKINE compounds through the sale of additional equity securities or otherwise; that the Company’s proposed products may be unsafe or ineffective for any or all of their proposed indications; and that clinical studies may at any point be suspended or take substantially longer than anticipated to complete. As discussed in the Company’s Securities and Exchange Commission filings, the Company’s proposed products would require additional research, lengthy and costly clinical testing and regulatory approval. The AMPAKINE compounds are investigational drugs and have not yet been shown to have efficacy in the treatment of any disease.